瑞替普酶与尿激酶在急性心肌梗死患者溶栓治疗中的作用比较

目的对比研究瑞通立（化学名为瑞替普酶）与尿激酶在急性ST段抬高心肌梗死（STEMI）患者溶栓治疗中的疗效及安全性。方法2007年8月～2011年9月收住本院的STEMI患者60例随机分为A组（瑞通立）和B组（尿激酶）各30例，观察两组血管总再通率、在发病3h内及3h后溶栓血管再通率、死亡率、出血及心律失常等并发症发生率以及120d左心室射血分数（LVEF）。结果A组总的血管再通率（86．66％）高于B组（63．33％），差异有统计学意义（P〈0．05）；两组在3h内较3h后溶栓的再通率有明显提高，但差异无统计学意义（P〉0．05）；A组死亡率、并发症及120dLVEF与B组比较，差异无统计学意义（P〉0．05）。结论溶栓治疗中瑞通立疗效优于尿激酶，两组在发病3h内溶栓冠脉再通率均高于3h后。

Comparison of thrombolytic therapy with Ruitongli and Urokinase in acute myocardial infarction

Objective To compare the efficacy and safety of Ruitongli(chemical called reteplase) and Urokinase in acute ST-segment elevation myocardial infarction(STEMI) in patients with thrombolytic therapy.Methods Sixty patients from August 2007 to September 2011 with STEMI admitted to our hospital were randomly divided into group A(Ruitongli) 30 cases,B group(Urokinase),30 cases were observed in the total patency rate of vascular,within 3 h and 3 h after in the incidence of recanalization after thrombolysis,mortality,complications such as bleeding and the incidence of arrhythmia,and 120 d left ventricular ejection fraction(LVEF).Results The overall recanalization rate:A group(86.66%) than in group B(63.33%)(P<0.05),significant difference;the two groups in within 3 h and 3 h after thrombolytic recanalization rate was significantly increase,but the difference was not statistically significant(P>0.05);A group of mortality,complications,and 120 d LVEF and B group,the difference was not statistically significant(P>0.05).Conclusion Thrombolytic therapy in Ruitongli establish more effective than Urokinase,the coronary thrombolysis reperfusion incidence of the two groups within 3 h were higher than the 3 h after.